The Tesamorelin / Ipamorelin Blend pairs two growth-hormone-axis research compounds in one vial: Tesamorelin, a stabilized GHRH analog, and Ipamorelin, a selective GHS-R1a agonist acting through a separate receptor pathway. No published study of this exact combination has been identified. Available in 6mg/3mg and 13mg/3mg for laboratory research use only.
HPLC certified
Independent analysis
Highest standard
Full traceability
Each order ships as a combined-vial Tesamorelin / Ipamorelin research compound in your choice of 6mg/3mg or 13mg/3mg, manufactured for laboratory use only.
| Product | Tesamorelin / Ipamorelin Blend |
|---|---|
| Components | Tesamorelin (GHRH analog) and Ipamorelin (selective GHS-R1a agonist) |
| Approved Pharmaceutical Comparator | Tesamorelin is the active ingredient in Egrifta/Egrifta SV, an FDA-approved prescription drug for reducing excess visceral fat in HIV patients with lipodystrophy. That approval does not extend to this research listing. |
| Labeled Composition | 6mg/3mg or 13mg/3mg as printed on the label. Whether each number is the milligram amount of each named component has not been independently confirmed beyond the label itself. |
| Purity | Not independently verified — no batch-specific COA is currently published |
| Identity | Not independently confirmed by mass spectrometry or an equivalent method |
| Available Sizes | 6mg/3mg / 13mg/3mg |
| Intended Use | Laboratory research only (RUO) |
When your order arrives, match the lot number printed on the vial to the lot number on the COA before beginning any work. Until a batch-specific COA is published for this blend, treat any purity or identity figure shown elsewhere on this listing as a supplier claim, not an independently verified result.
Tesamorelin and ipamorelin act on different GH pathways — here's what the human evidence on each shows, and why no study of the combination exists.
What is Ipamorelin? See what research shows about its mechanism, potential benefits, safety signals, and current FDA regulatory status for researchers.
HCG and LH bind the exact same receptor — yet research shows they send measurably different signals once they do. Here's what's actually established about HCG's structure, mechanism, and the FDA's position on HCG weight-loss claims.
